Tag: cagrilintide
-
CagriSema: Dual Amylin and GLP-1 Agonism in Clinical Trials
CagriSema combines the long-acting amylin analogue cagrilintide with semaglutide. Here is what Phase 3 REDEFINE 1 trial data demonstrate regarding its dual mechanism, 22.7% weight loss efficacy and current FDA NDA review.